Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 10:12:708280.
doi: 10.3389/fmicb.2021.708280. eCollection 2021.

In vitro Antifungal Susceptibility Profiles of Cryptococcus neoformans var. grubii and Cryptococcus gattii Clinical Isolates in Guangxi, Southern China

Najwa Al-Odaini  1   2 , Xiu-Ying Li  1   2 , Bing-Kun Li  1   2 , Xing-Chun Chen  3 , Chun-Yang Huang  1   2 , Chun-Ying Lv  1   2 , Kai-Su Pan  1   2 , Dong-Yan Zheng  1   2 , Yan-Qing Zheng  2   4 , Wan-Qing Liao  5 , Cun-Wei Cao  1   2
Affiliations

In vitro Antifungal Susceptibility Profiles of Cryptococcus neoformans var. grubii and Cryptococcus gattii Clinical Isolates in Guangxi, Southern China

Najwa Al-Odaini et al. Front Microbiol. .

Abstract

This study analyzed the in vitro drug sensitivity of Cryptococcus spp. from Guangxi, Southern China. One hundred three strains of Cryptococcus were recovered from 86 patients; 14 were HIV positive and 72 were HIV negative. Ninety-two strains were identified as Cryptococcus neoformans var. grubii, while 11 strains were identified as Cryptococcus gattii (5 C. gattii sensu stricto and 6 Cryptococcus deuterogattii). The recovered strains were tested against commonly used antifungal drugs (fluconazole, amphotericin B, 5-fluorocytosine, itraconazole, and voriconazole) and to novel antifungal drugs (posaconazole and isavuconazole) using CLSI M27-A4 method. The results showed that all isolates were susceptible to most antifungal drugs, of which the minimum inhibitory concentration (MIC) ranges were as follows: 0.05-4 μg/ml for fluconazole, 0.25-1 μg/ml for amphotericin B; 0.0625-2 μg/ml for 5-fluorocytosine, 0.0625-0.25 μg/ml for itraconazole, 0.0078-0.25 μg/ml for voriconazole, 0.0313-0.5 μg/ml for posaconazole, 0.0020-0.125 μg/ml for isavuconazole for C. neoformans var. grubii isolates, and 1-16 μg/ml for fluconazole, 0.125-1 μg/ml for 5-fluorocytosine, 0.25-1 μg/ml for amphotericin B, 0.0625-0.25 μg/ml for itraconazole, 0.0156-0.125 μg/ml for voriconazole, 0.0156-0.25 μg/ml for posaconazole, and 0.0078-0.125 μg/ml for isavuconazole for C. gattii isolates. Furthermore, some C. neoformans var. grubii isolates were found to be susceptible-dose dependent to 5-fluorocytosine and itraconazole. In addition, a reduction in the potency of fluconazole against C. gattii is possible. We observed no statistical differences in susceptibility of C. neoformans var. grubii and C. gattii in the tested strains. Continuous observation of antifungal susceptibility of Cryptococcus isolates is recommended to monitor the emergence of resistant strains.

Keywords: C. neoformans var. grubii; Cryptococcus gattii; Guangxi; in vitro drug sensitivity; variant identification.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Geographic distribution of cryptococcosis patients from Guangxi province, Southern China.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alves S. H., Oliveir L., Costa J. M., Lubeck I., Casali A. K., Vainstein M. H. (2001). In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil. Rev. Inst. Med. Trop. Sao Paulo 43 267–270. 10.1590/s0036-46652001000500006 - DOI - PubMed
    1. Arsic Arsenijevic V., Pekmezovic M. G., Meis J. F., Hagen F. (2014). Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates. Mycoses 57 380–387. - PubMed
    1. Bertout S., Drakulvoski P., Kouanfack C., Krasteva D., Ngouana T., Dunyach-Rémy C. (2013). Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients. Clin. Microbiol. Infect. 19 763–769. 10.1111/1469-0691.12019 - DOI - PubMed
    1. Chen J., Varma A., Diaz M. R., Litvintseva A. P., Wollenberg K. K., Kwon-Chung K. J. (2008). Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg. Infect. Dis. 14 755–762. 10.3201/eid1405.071312 - DOI - PMC - PubMed
    1. Chen Y., Yu F., Bian Z. Y., Hong J. M., Zhang N., Zhong Q. S., et al. (2018). Multilocus sequence typing reveals both shared and unique genotypes of Cryptococcus neoformans in Jiangxi Province, China. Sci. Rep. 24:1495. - PMC - PubMed